15.31 (-%)
As of Feb 16, 2024
Source:
We are a biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Our VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which we believe will induce broad, robust, and durable protection against the specific viruses targeted.
Country | United States |
Headquarters | seattle, washington |
Phone Number | (206) 737-0085 |
Industry | |
CEO | Adam Simpson |
Website | www.icosavax.com |